HomeNWOConVidVAERS-reported new-onset seizures following use of COVID-19 vaccinations as compared to influenza...

VAERS-reported new-onset seizures following use of COVID-19 vaccinations as compared to influenza vaccinations


The incidence of new-onset seizures, which we defined as de novo seizures occurring within 4 weeks of receiving any of the US Food and Drug Administration-approved COVID-19 vaccinations as reported in patient-reported data compiled in the US Centers for Disease Control and Prevention Vaccine Adverse Events Reporting System Data (CDC VAERS), has not been explored. The VAERS database contains de-identified patient-reported adverse events following vaccination and represents post-marketing surveillance and analysis of vaccine safety. After adjusting for time at risk, this resulted in estimated incidence rates of 3.19 seizures per 100 000 persons per year for the COVID-19 vaccine and 0.090 seizures per 100 000 persons per year for the influenza vaccines. A data-driven, individualized dataset that is comprehensive and coupled with a longitudinal follow-up in larger numbers of vaccinated individuals is needed to expand on our preliminary findings of vaccine-related seizures.

Keywords: COVID-19; Johnson and Johnson vaccine; Moderna vaccine; Pfizer vaccine; VAERS data; influenza vaccine; seizures.

© 2022 British Pharmacological Society.

Conflict of interest statement

The authors declare no conflict of interest with any of the products listed in the study.

Similar articles

Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, Braun MM, Chen RT.MMWR Surveill Summ. 2003 Jan 24;52(1):1-24.PMID: 12825543

Formeister EJ, Wu MJ, Chari DA, Meek R 3rd, Rauch SD, Remenschneider AK, Quesnel AM, de Venecia R, Lee DJ, Chien W, Stewart CM, Galaiya D, Kozin ED, Sun DQ.JAMA Otolaryngol Head Neck Surg. 2022 Apr 1;148(4):307-315. doi: 10.1001/jamaoto.2021.4414.PMID: 35201274

Martin D, Menschik D, Bryant-Genevier M, Ball R.Drug Saf. 2013 Jul;36(7):547-56. doi: 10.1007/s40264-013-0051-9.PMID: 23657824

Moro PL, Li R, Haber P, Weintraub E, Cano M.Expert Opin Drug Saf. 2016 Sep;15(9):1175-83. doi: 10.1080/14740338.2016.1194823. Epub 2016 Jun 16.PMID: 27268157 Free PMC article. Review.

Haber P, Moro PL, Lewis P, Woo EJ, Jankosky C, Cano M.Vaccine. 2016 May 11;34(22):2507-12. doi: 10.1016/j.vaccine.2016.03.048. Epub 2016 Mar 23.PMID: 27015735 Free PMC article. Review.

See all similar articles

Cited by

Pandit T, Pandit R, Goyal L.Cureus. 2022 Oct 13;14(10):e30276. doi: 10.7759/cureus.30276. eCollection 2022 Oct.PMID: 36258808 Free PMC article.


  1. Mathieu E, Ritchie H, Ortiz‐Ospina E, et al. A global database of CoVID 19 vaccinations. Nat Hum Behav. 2021;5(7):947‐953. doi:10.1038/s41562-021-01122-8 – DOI – PubMed
  2. Gee J, Marquez P, Su J, et al. First month of CoVID 19 vaccination safety monitoring – United States, December 14, 2020 – January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(8):283‐288. doi:10.15585/mmwr.mm7008e3 – DOI – PMC – PubMed
  3. Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2015;33(36):4398‐4405. doi:10.1016/j.vaccine.2015.07.035 – DOI – PMC – PubMed
  4. Goss AL, Samudralwar RD, Das RR, Nath A. ANA investigates: Neurological complications of CoVID 19 vaccines. Ann Neurol. 2021;89(5):856‐857. doi:10.1002/ana.26065 – DOI – PMC – PubMed
  5. Chen G, Li X, Sun M, et al. COVID‐19 mRNA vaccines are generally safe in the short term: A vaccine vigilance real‐world study says. Front Immunol. 2021;12:669010. doi:10.3389/fimmu.2021.669010 – DOI – PMC – PubMed



Please enter your comment!
Please enter your name here

Popular Articles